Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot… - … England Journal of …, 2017 - Mass Medical Soc
Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
A Hochhaus, RA Larson, F Guilhot, JP Radich… - 2017 - pubmed.ncbi.nlm.nih.gov
Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot, JP Radich… - NEW ENGLAND …, 2017 - arpi.unipi.it
BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot… - … England Journal of …, 2017 - ohsu.elsevierpure.com
BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, R Larson, F Guilhot, J Radich… - 2017 - digital.library.adelaide.edu.au
BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
[HTML][HTML] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
A Hochhaus, RA Larson, F Guilhot… - The New England …, 2017 - ncbi.nlm.nih.gov
BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
[引用][C] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
IRIS Investigators - New England …, 2017 - researchinformation.amsterdamumc …
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia — Amsterdam UMC
research portal Skip to main navigation Skip to search Skip to main content Amsterdam UMC …
research portal Skip to main navigation Skip to search Skip to main content Amsterdam UMC …
[PDF][PDF] Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
A Hochhaus, RA Larson, F Guilhot, JP Radich… - N Engl J …, 2017 - baranpharmaco.ir
BACKGROUND Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot… - … England Journal of …, 2017 - research.sahmri.org.au
BACKGROUND: Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
A Hochhaus, RA Larson, F Guilhot… - New England Journal …, 2017 - eprints.ncl.ac.uk
RESULTS The median follow-up was 10.9 years. Given the high rate of crossover among
patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) …
patients who had been randomly assigned to receive interferon alfa plus cytarabine (65.6%) …